ABVC Biopharma Inc.
11/03/2025 | Press release | Distributed by Public on 11/03/2025 06:30
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 (Form 8-K)
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
Silicon Valley, CA (November 03, 2025) - ABVC BioPharma, Inc.. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced its financial results for the quarter ended September 30, 2025, and provided an update on recent corporate developments.
Valuations provided above are based on third-party valuation.
Financial Highlights
| ● | Licensing Revenue: The Company recognized approximately USD 1.28 million in licensing revenue for Q3 2025, compared to USD 0.39 million for the same period in 2024, an increase of approximately 230% year-over-year. |
| ● | Total Assets: As of September 30, 2025, total assets were USD 21.18 million, compared with USD 7.54 million at December 31, 2024, representing an increase of approximately 181%. |
| ● | Property and Equipment: Property and equipment (net) totaled USD 12.06 million, up from USD 0.51 million at the end of 2024, reflecting a growth of approximately 2,100% due to recent real-asset investments in Taiwan. |
Operational Highlights
| ● | Strategic Asset Investments: During the third quarter, the Company completed two land acquisitions in Taiwan totaling approximately USD 11 million: |
| ● | Puli (Nantou) by AiBtl BioPharma Inc.: USD 7.67 million for the development of a plant factory for botanical raw materials and new drug substance research. |
| ● | Longtan (Taoyuan) by ABVC BioPharma, Inc.: USD 3.3 million for agricultural R&D and API cultivation. These investments, together with the planned Vitargus® GMP manufacturing facility, are expected to strengthen the Company's Asia-based production and research capabilities. |
| ● | Global Dual-Core Structure: ABVC continues to develop its dual-core operations between Silicon Valley, focusing on innovation and clinical development through its BioKey platform, and Taiwan, which supports manufacturing and development activities. |
| ● | Licensing Programs: The Company maintains multiple licensing agreements covering CNS, ophthalmology, and oncology pipelines, each providing potential future milestone and royalty income based on development and commercialization progress. |
Corporate Overview
The Company continues to follow an asset-light business model focused on licensing, partnerships, and collaborative development. Recent investments in physical assets in Taiwan are expected to enhance future research and manufacturing capacity. ABVC seeks to advance its key pipeline assets and to explore additional partnerships that support its long-term growth strategy.
"Our third-quarter results reflect continued progress in both our licensing revenue and asset development activities," said Dr. Uttam Patil, ABVC's Chief Executive Officer. "We remain focused on executing our strategic priorities to create sustainable value for our shareholders over the long term."
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
ABVC Biopharma Inc. published this content on November 03, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 03, 2025 at 12:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]